1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Modality
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL ANTI RADIATION DRUGS MARKET, BY COMPOUND
6.1. Overview
6.2. Potassium lodide (Kl)
6.3. Prussian Blue
6.4. DTPA (Diethylenetriamine Pentaacetate)
6.5. Others
7. GLOBAL ANTI RADIATION DRUGS MARKET, BY APPLICATION
7.1. Overview
7.2. Acute Radiation Syndrome (ARS)
7.3. Cancer Treatment
7.4. Radiation Exposure
7.5. Others
8. GLOBAL ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL
8.1. Overview
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
8.4. Others
9. GLOBAL ANTI RADIATION DRUGS MARKET, BY REGION
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. India
9.4.3. Japan
9.4.4. South Korea
9.4.5. Australia
9.4.6. Rest of Asia-Pacific
9.5. Rest of the World
9.5.1. Middle East
9.5.2. Africa
9.5.3. Latin America
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Anti radiation drugs Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Anti radiation drugs Market,
10.7. Key developments and Growth Strategies
10.7.1. New Compound Launch/Application Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2022
10.8.2. Major Players R&D Expenditure. 2022
11. COMPANY PROFILES
11.1. Amgen Inc.
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Compounds Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Anbex Inc.
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Compounds Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Arco Pharmaceuticals LLC
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Compounds Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. BTG International Inc.
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Compounds Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Cellphire, Inc.
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Compounds Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. CHRYSALIS BIOTHERAPEUTICS, INC.
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Compounds Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Darnitsa
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Compounds Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Enzychem Lifesciences Corporation
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Compounds Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Humanetics Corporation
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Compounds Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Mission Pharmacal Company
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Compounds Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Myelo Therapeutics GmbH
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Compounds Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Partner Therapeutics
11.12.1. Company Overview
11.12.2. Financial Overview
11.12.3. Compounds Offered
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Pluri Inc.
11.13.1. Company Overview
11.13.2. Financial Overview
11.13.3. Compounds Offered
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL ANTI RADIATION DRUGS MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL ANTI RADIATION DRUGS MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 5 GLOBAL ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 7 NORTH AMERICA ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 8 NORTH AMERICA ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 9 NORTH AMERICA ANTI RADIATION DRUGS MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 10 U.S. ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 11 U.S. ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 12 U.S. ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 13 CANADA ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 14 CANADA ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 15 CANADA ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 16 EUROPE ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 17 EUROPE ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 18 EUROPE ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 19 EUROPE ANTI RADIATION DRUGS MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 20 GERMANY ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 21 GERMANY ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 22 GERMANY ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 23 FRANCE ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 24 FRANCE ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 25 FRANCE ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 26 ITALY ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 27 ITALY ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 28 ITALY ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 29 SPAIN ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 30 SPAIN ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 31 SPAIN ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 32 U.K ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 33 U.K ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 34 U.K ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 35 REST OF EUROPE ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 36 REST OF EUROPE ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 37 REST OF EUROPE ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 38 ASIA PACIFIC ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 39 ASIA PACIFIC ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 40 ASIA PACIFIC ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 41 ASIA PACIFIC ANTI RADIATION DRUGS MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 42 JAPAN ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 43 JAPAN ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 44 JAPAN ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 45 CHINA ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 46 CHINA ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 47 CHINA ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 48 INDIA ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 49 INDIA ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 50 INDIA ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 51 AUSTRALIA ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 52 AUSTRALIA ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 53 AUSTRALIA ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 54 SOUTH KOREA ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 55 SOUTH KOREA ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 56 SOUTH KOREA ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 57 REST OF ASIA-PACIFIC ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 58 REST OF ASIA-PACIFIC ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 59 REST OF ASIA-PACIFIC ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 60 REST OF WORLD ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 61 REST OF WORLD ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 62 REST OF WORLD ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 63 REST OF WORLD ANTI RADIATION DRUGS MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 64 MIDDLE EAST ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 65 MIDDLE EAST ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 66 MIDDLE EAST ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 67 AFRICA ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 68 AFRICA ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 69 AFRICA ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 70 LATIN AMERICA ANTI RADIATION DRUGS MARKET, BY COMPOUND, 2018-2032 (USD BILLION)
TABLE 71 LATIN AMERICA ANTI RADIATION DRUGS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 72 LATIN AMERICA ANTI RADIATION DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION) 
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ANTI RADIATION DRUGS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ANTI RADIATION DRUGS MARKET
FIGURE 4 GLOBAL ANTI RADIATION DRUGS MARKET, SHARE (%), BY COMPOUND, 2022
FIGURE 5 GLOBAL ANTI RADIATION DRUGS MARKET, SHARE (%), BY APPLICATION, 2022
FIGURE 6 GLOBAL ANTI RADIATION DRUGS MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2022
FIGURE 7 GLOBAL ANTI RADIATION DRUGS MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 NORTH AMERICA: ANTI RADIATION DRUGS MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 EUROPE: ANTI RADIATION DRUGS MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 ASIA-PACIFIC: ANTI RADIATION DRUGS MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 REST OF THE WORLD: ANTI RADIATION DRUGS MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 GLOBAL ANTI RADIATION DRUGS MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 13 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 AMGEN INC.: SWOT ANALYSIS
FIGURE 15 ANBEX INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 ANBEX INC.: SWOT ANALYSIS
FIGURE 17 ARCO PHARMACEUTICALS LLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 ARCO PHARMACEUTICALS LLC: SWOT ANALYSIS
FIGURE 19 BTG INTERNATIONAL INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 BTG INTERNATIONAL INC.: SWOT ANALYSIS
FIGURE 21 CELLPHIRE, INC..: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 CELLPHIRE, INC..: SWOT ANALYSIS
FIGURE 23 CHRYSALIS BIOTHERAPEUTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 CHRYSALIS BIOTHERAPEUTICS, INC.: SWOT ANALYSIS
FIGURE 25 DARNITSA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 DARNITSA: SWOT ANALYSIS
FIGURE 27 ENZYCHEM LIFESCIENCES CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 ENZYCHEM LIFESCIENCES CORPORATION: SWOT ANALYSIS
FIGURE 29 HUMANETICS CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 HUMANETICS CORPORATION: SWOT ANALYSIS
FIGURE 31 MISSION PHARMACAL COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 MISSION PHARMACAL COMPANY: SWOT ANALYSIS
FIGURE 33 MYELO THERAPEUTICS GMBH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 MYELO THERAPEUTICS GMBH: SWOT ANALYSIS
FIGURE 35 PARTNER THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 PARTNER THERAPEUTICS: SWOT ANALYSIS
FIGURE 37 PLURI INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 PLURI INC.: SWOT ANALYSIS
